Dr. Jennifer McVean, MD, stands at the forefront of pediatric diabetes care, blending her personal journey with Type 1 diabetes and her extensive medical expertise to transform treatment approaches for children and families worldwide.
Diagnosed with Type 1 diabetes at the age of 11, Dr. McVean’s firsthand experience has profoundly influenced her compassionate and innovative approach to patient care. Her dedication is evident in her role as Senior Director of Medical Affairs for Medtronic Diabetes, where she spearheads advancements in diabetes technology and treatment strategies.
Professional Journey and Expertise
Dr. McVean’s academic and professional path reflects her commitment to excellence. She earned her medical degree from the University of Minnesota Medical School, completed her pediatric residency at the University of Colorado, and pursued a fellowship in Pediatric Endocrinology and Diabetes at the University of Wisconsin. Board-certified in both Pediatrics and Pediatric Endocrinology, she has held esteemed positions at institutions such as the University of Minnesota, Children’s Minnesota, and Gundersen Health System.
Her areas of specialization include:
- Type 1 Diabetes
- Pediatric Diabetes Management
- Insulin Pump Therapy
- Continuous Glucose Monitoring (CGM)
- Growth and Thyroid Disorders
- Diabetes Technology and Innovation
- Clinical Research and Medical Affairs Leadership
Contributions to Diabetes Research and Technology
Dr. McVean’s research has significantly impacted the field of diabetes care. Notably, she co-authored a study published in JAMA titled “Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial,” which explored the benefits of stringent glucose control in preserving pancreatic function in children newly diagnosed with Type 1 diabetes.
In her role at Medtronic Diabetes, Dr. McVean has been instrumental in the development and implementation of advanced insulin delivery systems. Her work on the MiniMed™ 780G system demonstrated its efficacy in improving overnight glycemic control and reducing the burden on patients, as detailed in a study published in Diabetes, Obesity and Metabolism.
Advocacy and Community Engagement
Beyond her clinical and research endeavors, Dr. McVean is deeply involved in diabetes advocacy and education. She has collaborated with organizations such as the Juvenile Diabetes Research Foundation (JDRF), the American Diabetes Association (ADA), and the Pediatric Endocrine Society. Her efforts focus on raising awareness, promoting early detection, and supporting initiatives aimed at improving the quality of life for individuals with diabetes.
Dr. Jennifer McVean has become a respected voice in the Type 1 Diabetes community through her leadership, advocacy, and commitment to advancing diabetes care. Living with Type 1 Diabetes herself, Dr. McVean brings both personal experience and medical expertise to the search for better treatments and, ultimately, a cure.
Her work has helped accelerate awareness of emerging disease-modifying therapies, early detection programs, advanced insulin delivery systems, and next-generation cell-based treatments that are changing the future of Type 1 Diabetes care. Researchers worldwide are now making significant progress toward therapies that may delay, prevent, or one day eliminate the need for lifelong insulin dependence.
As a physician, educator, and advocate, Dr. McVean continues to support groundbreaking research efforts aimed at preserving insulin-producing cells, improving quality of life, and moving the medical community closer to a world without Type 1 Diabetes. While no definitive cure has yet been approved, the pace of innovation has never been greater, and leaders like Dr. McVean are helping drive that progress forward.
For more information about Dr. Jennifer McVean and her contributions to pediatric diabetes care, visit her profile at Hudson Physicians.